目的:评估不同阶段结肠腺癌患者中CDC样激酶2 (CLK2)基因的表达,以及CLK2在结肠腺癌细胞中的表达变化和CLK2所介导的细胞功能。方法:在TIMER数据库和GEPIA数据库分析CLK2在健康与不同肿瘤组织中的表达水平,找到差异性表达显著的肿瘤类...目的:评估不同阶段结肠腺癌患者中CDC样激酶2 (CLK2)基因的表达,以及CLK2在结肠腺癌细胞中的表达变化和CLK2所介导的细胞功能。方法:在TIMER数据库和GEPIA数据库分析CLK2在健康与不同肿瘤组织中的表达水平,找到差异性表达显著的肿瘤类型。分析TCGA数据库中各个阶段结肠腺癌患者组织中CLK2的表达水平变化。使用RT-qPCR和western blot方法检测了CLK2基因在肿瘤组织和细胞系中的表达变化。在敲低CLK2的条件下,使用western blot方法检测细胞增殖标志物和细胞周期标志物的表达。最后,使用STRING工具分析与CLK2基因相关性较强的多个关键基因。结果:结肠腺癌组织中的CLK2基因表达显著升高(p Objective: To assess CDC-like kinase 2 (CLK2) gene expression in patients with different stages of colon adenocarcinoma, as well as changes in CLK2 expression in colon adenocarcinoma cells and cellular functions mediated by CLK2. Methods: Screening for CLK2 differentially expressed tumor types in the TIMER database and the GEPIA database. Detection of CLK2 gene changes with colon adenocarcinoma tumor stage in the TCGA database. Changes in CLK2 gene expression in tumor tissues and cell lines were detected using RT-qPCR and western blot methods. The expressions of cell proliferation markers and cell cycle markers were detected using western blot method under the condition of knocking down CLK2. Finally, multiple key genes with strong correlation with CLK2 gene were analyzed using STRING tool. Results: CLK2 gene expression was significantly elevated in colon adenocarcinoma tissues (p < 0.001), and the high expression of CLK2 gene was significantly correlated with the clinical features of colon adenocarcinoma (pathological stage, T stage) (p < 0.05). CLK2 gene expression is elevated in colon adenocarcinoma cells, and knockdown of CLK2 expression can effectively inhibit cell proliferation and cell cycle. Finally, CLK3, CLK1, SRSF12 and other genes are potential binding targets of CLK2 gene. Conclusion: The expression level of the CLK2 gene is significantly correlated with the progression of colon adenocarcinoma, and decreasing the expression of the CLK2 gene is expected to be a new approach to the treatment of patients with colon adenocarcinoma.展开更多
The accumulation of basic researches and clinical studies related to cytokine-induced killer(CIK) cells has confirmed their safety and feasibility in treating malignant diseases.This review summarizes the available pu...The accumulation of basic researches and clinical studies related to cytokine-induced killer(CIK) cells has confirmed their safety and feasibility in treating malignant diseases.This review summarizes the available published literature related to the biological characteristics and clinical applications of CIK cells in recent years.A number of clinical trials with CIK cells have been implemented during the progressive phases of cancer,presenting potential widespread applications of CIK cells for the future.Furthermore,this review briefly compares clinical applications of CIK cells with those of other adoptive immunotherapeutic cells.However,at present,there are no uniform criteria or large-scale preparations of CIK cells.The overall clinical response is difficult to evaluate because of the use of autologous CIK cells.Based on these observations,several suggestions regarding uniform criteria and universal sources for CIK cell preparations and the use of CIK cells either combined with chemotherapy or alone as a primary strategy are briefly proposed in this review.Large-scale,controlled,grouped,and multi-center clinical trials on CIK cell-based immunotherapy should be conducted under strict supervision.These interventions might help to improve future clinical applications and increase the clinical curative effects of CIK cells for a broad range of malignancies in the future.展开更多
Clk/STY is a LAMMER protein kinase capable to phosphorylate serine/arginine-rich (SR) proteins that modulate pre-mRNA splicing. Clk/STY alternative splicing generates transcripts encoding a full-length kinase and a tr...Clk/STY is a LAMMER protein kinase capable to phosphorylate serine/arginine-rich (SR) proteins that modulate pre-mRNA splicing. Clk/STY alternative splicing generates transcripts encoding a full-length kinase and a truncated catalyti-cally inactive protein. Here we showed that clk/STY, as well as other members of the family (e.g. clk2, clk3 and clk4),are up-regulated during HMBA-induced erythroleukemia cell differentiation. mRNAs coding for the full-length and thetruncated forms were responsible for the overall increased expression. In clk/STY, however, a switch was observed forthe ratio of the two alternative spliced products. In undifferentiated cells the full-length transcript was more abundantwhereas the transcript encoding for the truncated form predominated at latter stages of differentiation. Surprisingly,overexpression of clk/STY did not alter the splicing switch upon differentiation in MEL cells. These results suggest thatclk/STY might contribute to control erythroid differentiation by a mechanism that implicates a balance between thesetwo isoforms.展开更多
文摘目的:评估不同阶段结肠腺癌患者中CDC样激酶2 (CLK2)基因的表达,以及CLK2在结肠腺癌细胞中的表达变化和CLK2所介导的细胞功能。方法:在TIMER数据库和GEPIA数据库分析CLK2在健康与不同肿瘤组织中的表达水平,找到差异性表达显著的肿瘤类型。分析TCGA数据库中各个阶段结肠腺癌患者组织中CLK2的表达水平变化。使用RT-qPCR和western blot方法检测了CLK2基因在肿瘤组织和细胞系中的表达变化。在敲低CLK2的条件下,使用western blot方法检测细胞增殖标志物和细胞周期标志物的表达。最后,使用STRING工具分析与CLK2基因相关性较强的多个关键基因。结果:结肠腺癌组织中的CLK2基因表达显著升高(p Objective: To assess CDC-like kinase 2 (CLK2) gene expression in patients with different stages of colon adenocarcinoma, as well as changes in CLK2 expression in colon adenocarcinoma cells and cellular functions mediated by CLK2. Methods: Screening for CLK2 differentially expressed tumor types in the TIMER database and the GEPIA database. Detection of CLK2 gene changes with colon adenocarcinoma tumor stage in the TCGA database. Changes in CLK2 gene expression in tumor tissues and cell lines were detected using RT-qPCR and western blot methods. The expressions of cell proliferation markers and cell cycle markers were detected using western blot method under the condition of knocking down CLK2. Finally, multiple key genes with strong correlation with CLK2 gene were analyzed using STRING tool. Results: CLK2 gene expression was significantly elevated in colon adenocarcinoma tissues (p < 0.001), and the high expression of CLK2 gene was significantly correlated with the clinical features of colon adenocarcinoma (pathological stage, T stage) (p < 0.05). CLK2 gene expression is elevated in colon adenocarcinoma cells, and knockdown of CLK2 expression can effectively inhibit cell proliferation and cell cycle. Finally, CLK3, CLK1, SRSF12 and other genes are potential binding targets of CLK2 gene. Conclusion: The expression level of the CLK2 gene is significantly correlated with the progression of colon adenocarcinoma, and decreasing the expression of the CLK2 gene is expected to be a new approach to the treatment of patients with colon adenocarcinoma.
基金supported by the grants from the National Natural Science Foundation of China(31270820,81230061 and 81402566)partially supported by a grant from the 2013BA101B00
文摘The accumulation of basic researches and clinical studies related to cytokine-induced killer(CIK) cells has confirmed their safety and feasibility in treating malignant diseases.This review summarizes the available published literature related to the biological characteristics and clinical applications of CIK cells in recent years.A number of clinical trials with CIK cells have been implemented during the progressive phases of cancer,presenting potential widespread applications of CIK cells for the future.Furthermore,this review briefly compares clinical applications of CIK cells with those of other adoptive immunotherapeutic cells.However,at present,there are no uniform criteria or large-scale preparations of CIK cells.The overall clinical response is difficult to evaluate because of the use of autologous CIK cells.Based on these observations,several suggestions regarding uniform criteria and universal sources for CIK cell preparations and the use of CIK cells either combined with chemotherapy or alone as a primary strategy are briefly proposed in this review.Large-scale,controlled,grouped,and multi-center clinical trials on CIK cell-based immunotherapy should be conducted under strict supervision.These interventions might help to improve future clinical applications and increase the clinical curative effects of CIK cells for a broad range of malignancies in the future.
文摘Clk/STY is a LAMMER protein kinase capable to phosphorylate serine/arginine-rich (SR) proteins that modulate pre-mRNA splicing. Clk/STY alternative splicing generates transcripts encoding a full-length kinase and a truncated catalyti-cally inactive protein. Here we showed that clk/STY, as well as other members of the family (e.g. clk2, clk3 and clk4),are up-regulated during HMBA-induced erythroleukemia cell differentiation. mRNAs coding for the full-length and thetruncated forms were responsible for the overall increased expression. In clk/STY, however, a switch was observed forthe ratio of the two alternative spliced products. In undifferentiated cells the full-length transcript was more abundantwhereas the transcript encoding for the truncated form predominated at latter stages of differentiation. Surprisingly,overexpression of clk/STY did not alter the splicing switch upon differentiation in MEL cells. These results suggest thatclk/STY might contribute to control erythroid differentiation by a mechanism that implicates a balance between thesetwo isoforms.
